Search Results - "ZANON, E."

Albumin-Fusion Recombinant FIX in the Management of People with Hemophilia B: An Evidence-Based Review by Pasca, Samantha, Zanon, Ezio

“…Albutrepenonacog-alfa (Idelvion[R], CSL Behring) is a recombinant fusion protein in which the recombinant FIX (rFIX) links a recombinant human albumin,…”
Get full text

Type 3 von Willebrand disease mistaken for moderate haemophilia A: a lesson still to be learned by Galletta, E., Daidone, V., Zanon, E., Casonato, S.

Get full text

Cerebrovascular diseases in hemophiliacs: A real, but underestimated risk by Zanon, E., Milan, M., Sarolo, L., Pasca, S.

Get full text

Pharmacokinetics of plasma-derived vs. recombinant FVIII concentrates: a comparative study by Morfini, M., Marchesini, E., Paladino, E., Santoro, C., Zanon, E., Iorio, A.

“…Summary Only very few pharmacokinetic (PK) studies comparing plasma derived FVIII (pd‐FVIII) against recombinant FVIII (rFVIII) concentrates are available. The…”
Get full text

Potential biomarkers of haemophilic arthropathy: correlations with compatible additive magnetic resonance imaging scores by Oldenburg, J., Zimmermann, R., Katsarou, O., Zanon, E., Kellermann, E., Lundin, B., Ellinghaus, P.

“…Introduction Although biomarkers are useful diagnostic tools to assess joint damage in osteoarthritis and rheumatoid arthritis, few data exist for biomarkers…”
Get full text

Controlled, cross-sectional MRI evaluation of joint status in severe haemophilia A patients treated with prophylaxis vs. on demand by Oldenburg, J., Zimmermann, R., Katsarou, O., Theodossiades, G., Zanon, E., Niemann, B., Kellermann, E., Lundin, B.

“…Summary In patients with haemophilia A, factor VIII (FVIII) prophylaxis reduces bleeding frequency and joint damage compared with on‐demand therapy. To assess…”
Get full text

Low dose of aPCC after the initial treatment in acquired haemophilia A is useful to reduce bleeding relapses: Data from the FAIR registry by Zanon, E., Pasca, S., Siragusa, S., Napolitano, M., Santoro, C., Mameli, L., Rocino, A.

“…Bypassing agents are the first line therapy in patients with acquired haemophilia A (AHA). Activated prothrombin complex concentrate (aPCC) proved to be…”
Get full text

Comorbidities in persons with haemophilia aged 60 years or more compared with age‐matched people from the general population by Marchesini, E., Oliovecchio, E., Coppola, A., Santagostino, E., Radossi, P., Castaman, G., Valdrè, L., Santoro, C., Tagliaferri, A., Ettorre, C., Zanon, E., Barillari, G., Cantori, I., Caimi, T. M., Sottilotta, G., Iorio, A., Mannucci, P. M.

Get full text

Combined use of antifibrinolytics and activated prothrombin complex concentrate (aPCC) is not related to thromboembolic events in patients with acquired haemophilia A: data from FAIR Registry by Pasca, S., Ambaglio, C., Rocino, A., Santoro, C., Cantori, I., Zanon, E.

“…Antifibrinolytics combined with aPCC are not routinely administered to patients with acquired hemophilia A due to increased thrombotic risk. This association…”
Get full text

Effects of secondary prophylaxis started in adolescent and adult haemophiliacs by TAGLIAFERRI, A., FRANCHINI, M., COPPOLA, A., RIVOLTA, G. F., SANTORO, C., ROSSETTI, G., FEOLA, G., ZANON, E., DRAGANI, A., IANNACCARO, P., RADOSSI, P., MANNUCCI, P. M.

“…While primary prophylaxis is a well‐established and recommended method of care delivery for children with severe haemophilia, fewer studies have documented the…”
Get full text

Confronting the psychological burden of haemophilia by COPPOLA, A., CERBONE, A. M., MANCUSO, G., MANSUETO, M. F., MAZZINI, C., ZANON, E.

“…Providing comprehensive care, counselling and support to haemophilic patients, and their parents have always been quite complex for haemophilia treatment…”
Get full text

Intracranial haemorrhage in the Italian population of haemophilia patients with and without inhibitors by ZANON, E., IORIO, A., ROCINO, A., ARTONI, A., SANTORO, R., TAGLIAFERRI, A., COPPOLA, A., CASTAMAN, G., MANNUCCI, P. M.

“…Intracranial haemorrhage (ICH) is the most serious bleeding symptom in haemophiliacs, resulting in high rates of mortality and disabling sequelae. The…”
Get full text

CO62 Prophylaxis Treatment for Patients With Hemophilia A Without Inhibitors: Experience Monitoring Survey on the Use of Damoctocog Alfa Pegol by Zanon, E

Get full text

Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: a case series by Iorio, A., Barbara, A. M., Makris, M., Fischer, K., Castaman, G., Catarino, C., Gilman, E., Kavakli, K., Lambert, T., Lassila, R., Lissitchkov, T., Mauser‐Bunschoten, E., Mingot‐Castellano, M. E., Ozdemir, N., Pabinger, I., Parra, R., Pasi, J., Peerlinck, K., Rauch, A., Roussel‐Robert, V., Serban, M., Tagliaferri, A., Windyga, J., Zanon, E.

“…Background Development of inhibitors is the most serious complication in haemophilia A treatment. The assessment of risk for inhibitor formation in new or…”
Get full text

Ultrasonographically-guided fine-needle aspiration of axillary lymph nodes: role in breast cancer management by SAPINO, A, CASSONI, P, ZANON, E, FRAIRE, F, CROCE, S, COLUCCIA, C, DONADIO, M, BUSSOLATI, G

“…The knowledge of the status of axillary lymph nodes (LN) of patients with breast cancer is a fundamental prerequisite in the therapeutic decision. In the…”
Get full text

Efficacy and safety of highly purified, doubly virus-inactivated VWF/FVIII concentrates in inherited von Willebrand's disease: results of an Italian cohort study on 120 patients characterized by bleeding severity score by FEDERICI, A. B., BARILLARI, G., ZANON, E., MAZZUCCONI, M. G., MUSSO, R., TARGHETTA, R., MANNUCCI, P. M.

“…The efficacy of highly purified VWF/FVIII concentrates with standardized ristocetin cofactor content (VWF:RCo) has been already proven in patients with von…”
Get full text

A completely automated CAD system for mass detection in a large mammographic database by Bellotti, R., De Carlo, F., Tangaro, S., Gargano, G., Maggipinto, G., Castellano, M., Massafra, R., Cascio, D., Fauci, F., Magro, R., Raso, G., Lauria, A., Forni, G., Bagnasco, S., Cerello, P., Zanon, E., Cheran, S. C., Lopez Torres, E., Bottigli, U., Masala, G. L., Oliva, P., Retico, A., Fantacci, M. E., Cataldo, R., De Mitri, I., De Nunzio, G.

“…Mass localization plays a crucial role in computer-aided detection (CAD) systems for the classification of suspicious regions in mammograms. In this article we…”
Get full text

High dose of human plasma-derived FVIII-VWF as first-line therapy in patients affected by acquired haemophilia A and concomitant cardiovascular disease: four case reports and a literature review by Zanon, E., Milan, M., Brandolin, B., Barbar, S., Spiezia, L., Saggiorato, G., Simioni, P., Baudo, F.

Get full text

Whole blood rotation thromboelastometry (ROTEM®) in nine severe factor V deficient patients and evaluation of the role of intraplatelets factor V by SPIEZIA, L., RADU, C., CAMPELLO, E., BULATO, C., BERTINI, D., BARILLARI, G., DE ANGELIS, V., PRADELLA, P., ZANON, E., SIMIONI, P.

“…Severe factor V (FV) deficiency (parahaemophilia) is a rare congenital hemorrhagic disorder characterized by very low or undetectable plasma FV levels and…”
Get full text

Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: results from an Italian prospective observational study in patients with von Willebrand disease by Castaman, G., Coppola, A., Zanon, E., Boeri, E., Musso, M., Siragusa, S., Federici, A. B., Mancuso, G., Barillari, G., Biasoli, C., Feola, G., Franchini, M., Moratelli, S., Gamba, G., Schinco, P., Valdrè, L., Dragani, A., Mazzucconi, G., Tagliaferri, A., Morfini, M.

“…Summary Von Willebrand disease (VWD) is an inherited bleeding disorder caused by the quantitative or qualitative deficiency of von Willebrand factor (VWF)…”
Get full text